Category:

Nicole Crisano, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Laura Joszt, assistant managing editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network

Walgreens Boots Alliance said Wednesday it would expand its global retail pharmacy operations by taking a 40% stake in Sinopharm Holding Guoda Drugstores Co. Ltd., a subsidiary of China National Accord Medicines Corporation...Sinopharm GuoDa “operates and franchises retail pharmacies across China,” a market that Walgreens CEO Stefano Pessina has said he wants to tap as the companies looks to faster growing and emerging markets to extend its reach...“It is China’s leading pharmacy chain,”,,,Alliance Boots has had a joint venture in China known as Guangzhou Pharmaceuticals, which is a drug wholesaler in China. The joint venture operates pharmacies under a local brand...

CVS Health said on Sunday that it had agreed to buy Aetna for about $69 billion in a deal that would combine the drugstore giant with one of the biggest health insurers in the United States and has the potential to reshape the nation’s health care industry...The transaction, one of the largest of the year, reflects the increasingly blurred lines between the traditionally separate spheres of a rapidly changing industry. It represents an effort to make both companies more appealing to consumers as health care that was once delivered in a doctor’s office more often reaches consumers over the phone, at a retail clinic or via an app...A combined CVS-Aetna could position itself as a formidable figure in this changing landscape. Together, the companies touch most of the basic health services that people regularly use, providing an opportunity to benefit consumers. CVS operates a chain of pharmacies and retail clinics that could be used by Aetna to provide care directly to patients, while the merged company could be better able to offer employers one-stop shopping for health insurance for their workers.

It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down...In fact, projected returns at 12 of the world’s top drugmakers have fallen to an eight-year low of only 3.2 percent...The disconnect reflects the rising cost of developing new drugs, meager peak sales expectations for individual products and the fact that younger biotechnology companies are accounting for a growing proportion of new products...So far this year, the Food and Drug Administration...has approved 41 novel drugs compared with 22 for the whole of 2016...It’s been a great year for approvals in 2017...But for the giants of the pharma world...things are not so rosy. This decade has seen shrinking profitability in their research labs, with the average internal rate of return down sharply from 10.1 percent in 2010 to 3.2 percent this year...A separate group of four large biotech companies are projected to enjoy an IRR nearly four times higher at 11.9 percent. The calculations are based on long-term sales forecasts...The biotech companies are seeing more success...biotechs typically had a leaner cost structure...

Nicole Crisano, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Nevada health officials on Tuesday said a bill aimed at curtailing opioid overprescription will keep decision-making in the hands of physicians, not lawmakers...The provisions of Assembly Bill 474, which the Legislature passed into law this year and takes effect on New Year’s Day, were explained to about 200 physicians Tuesday evening at a forum at Las Vegas City Hall...Daniel Burkhead, a physician at the Innovative Pain Care Center in Las Vegas, said the law asks doctors to exercise caution...The law mandates that doctors conduct mental health evaluations before issuing first-time opioid prescriptions, which will be limited to 14 days. The law also mandates that doctors register with the state’s Prescription Drug Monitoring Program...“(Lawmakers) did not want to take power out of the hands of physicians,” Burkhead said. “The law wants you to think, before writing that prescription, if this patient provides a high risk of that medication being diverted or abused or misused.”

A medical charity that lost a crucial stamp of approval from the U.S. government because it had worked too closely with its drug-company donors said it will decide in January whether it can continue to help patients pay for their prescriptions...the Caring Voice Coalition, one of the biggest patient-assistance charities in the U.S., said it is delaying offering patients financial help for 2018 until it decides what to do...“We are very concerned that we may not be able to remain as a long-term viable resource for individuals with chronic illness,”...the Office of Inspector General of the Department of Health and Human Services rescinded its favorable advisory opinion of the Caring Voice Coalition, in part because the charity had provided drugmakers with data that could help them see if their contributions were helping their own customers. That could potentially give drug companies greater power to raise prices, the HHS said. It was the first time the HHS has rescinded a favorable advisory opinion for a patient-assistance charity.

Translational Software recently became the latest in a growing number of health IT vendors creating systems to advance precision medicine with its debut of its PGx pediatric platform. Another precision medicine player stepped into the market...with a product designed to be integrated smack dab in the middle of a physician’s clinical workflow. 2bPrecise, a cloud-based precision medicine platform vendor and an Allscripts company, launched a pharmacogenomics (PGx) system to bring crucial data to the clinical workflow...2bPrecise Pgx...makes pharmacogenetic information accessible so physicians can make better informed treatment decisions based on a patient’s unique genetic makeup...The 2bPrecise PGx system plugs into an EHR’s native workflow and can integrate content from Translational Software (a genomic data-based clinical decision support system) and other knowledge sources to enable precision medicine-based decision making at the point of care. 2bPrecise’s PGx system is part of its larger precision medicine platform, built to capture and store genomic data from a range of sources, enabling the harmonization of clinical knowledge and genomic research to extract patient-specific insights.

Southern Nevada and the world watched as Las Vegas hospitals and doctors operated and cared for the wounded on Oct. 1 and subsequent days, and they’re getting high marks for their performance for handling the worst mass shooting in modern U.S. history...While 58 were killed — nearly all succumbed to their wounds at the scene of a country music concert on the Strip — more than 500 people were injured, and most passed through nine of Las Vegas’ 14 hospitals. More than 200 went to Sunrise Hospital and Medical Center, and more than 100 went to University Medical Center — the city’s two main trauma centers for handling emergency cases...The hospitals and the medical community are evaluating their performance for a wider report about lessons learned. That information will be disseminated across the country as doctors, nurses and administrators appear at panels in the coming months to share with professionals in their fields...Once hospitals complete their internal review, they will be shared with one another how they responded and what the challenges were...They will look at what they did well and how they would do something differently in the future...Las Vegas will share with the rest of the world the “best practices” it learned from the mass shooting, just like it did after the MGM Grand fire...